Forget a Cash ISA! I’d aim to make a passive income with these 2 FTSE 100 dividend stocks

I think these two FTSE 100 (INDEXFTSE:UKX) income shares appear to offer favourable prospects when compared to a Cash ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the best returns available on a Cash ISA are currently around 1.5%, buying FTSE 100 dividend shares could prove to be a shrewd move.

In many cases, it is possible to double, or even treble, your passive income when compared to Cash ISA rates.

With interest rates set to remain at their current level, or even fall, over the next few years, now could be a good time to buy these two large-cap income shares. They appear to have sound strategies that could produce capital growth alongside their income returns.

AstraZeneca

With a 3.1% dividend yield, AstraZeneca (LSE: AZN) may not be among the highest-yielding shares in the FTSE 100. However, the pharmaceutical company’s dividend growth prospects could make it a sound income opportunity for the long run.

Its recent updates have shown that its pipeline has improved dramatically in recent years after an ambitious investment programme. This could position the company for growth in a world where demographic challenges may catalyse demand for a wide range of healthcare products and services.

AstraZeneca’s defensive business model may prove to be attractive to many investors during what is a period of significant economic and political risk.

Furthermore, with its dividend expected to be covered 1.3 times by net profit in the current year, there seems to be scope for its shareholder payouts to rise at a brisk pace. This could lead to a strong and dependable passive income stream for its investors that catalyses its share price over the long run.

British Land

Real estate investment trust (REIT) British Land (LSE: BLND) is a very different investment proposition than AstraZeneca. The property company is facing a period of disruption across much of its asset base, with demand for retail units expected to come under pressure over the medium term as online shopping becomes increasingly popular.

This could cause rents to decline, which may put the company’s dividend growth rate under a degree of pressure. However, with British Land shifting its focus away from retail and towards faster-growing areas such as flexible office space, it seems to have a sound strategy that could lead to improving financial performance in the long run.

Furthermore, investors appear to have factored in the risks facing the business. It trades on a price-to-book (P/B) ratio of just 0.6, while its dividend yield of 5.4% is among the highest yields currently available in the FTSE 100.

Certainly, British Land may prove to be a relatively risky stock to own in the short run, as it aims to transition towards assets that have greater growth potential. For long-term income investors, now could be the right time to buy a slice of the business based on its high income return and wide margin of safety. It could offer high total returns in the coming years.

Peter Stephens owns shares of AstraZeneca and British Land Co. The Motley Fool UK has recommended AstraZeneca and British Land Co. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

ChatGPT thinks these are the 5 best FTSE stocks to consider buying for 2026!

Can the AI bot come up trumps when asked to select the best FTSE stocks to buy as we enter…

Read more »

Investing For Beginners

How much do you need in an ISA to make the average UK salary in passive income?

Jon Smith runs through how an ISA can help to yield substantial income for a patient long-term investor, and includes…

Read more »

Investing Articles

3 FTSE 250 shares to consider for income, growth, and value in 2026!

As the dawn of a new year in the stock market approaches, our writer eyes a trio of FTSE 250…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Want to be a hit in the stock market? Here are 3 things super-successful investors do

Dreaming of strong performance when investing in the stock market? Christopher Ruane shares a trio of approaches used by some…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

The BP share price has been on a roller coaster, but where will it go next?

Analysts remain upbeat about 2026 prospects for the BP share price, even as an oil glut threatens and the price…

Read more »

Investing Articles

Prediction: move over Rolls-Royce, the BAE share price could climb another 45% in 2026

The BAE Systems share price has had a cracking run in 2025, but might the optimism be starting to slip…

Read more »

Tesla car at super charger station
Investing Articles

Will 2026 be make-or-break for the Tesla share price?

So what about the Tesla share price: does it indicate a long-term must-buy tech marvel, or a money pit for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Apple CEO Tim Cook just put $3m into this S&P 500 stock! Time to buy?

One household-name S&P 500 stock has crashed 65% inside five years. Yet Apple's billionaire CEO sees value and has been…

Read more »